In vivo assessment of the effect of taxifolin glycoside on atopic dermatitis-like skin lesions using biomedical tools in NC/Nga mice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J. Y. | - |
dc.contributor.author | Lee, O. S. | - |
dc.contributor.author | Ha, S. | - |
dc.contributor.author | Kim, J. H. | - |
dc.contributor.author | Park, G. | - |
dc.contributor.author | Kim, J. K. | - |
dc.contributor.author | Oh, C. H. | - |
dc.date.accessioned | 2021-09-04T14:49:41Z | - |
dc.date.available | 2021-09-04T14:49:41Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2015-07 | - |
dc.identifier.issn | 0307-6938 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/93157 | - |
dc.description.abstract | BackgroundNoninvasive methods of assessment are widely used in clinical trials. However, such methods have not been established in atopic dermatitis (AD), which is a chronic inflammatory skin disease. AimTo demonstrate, using biomedical tools, the benefits of a new substance, taxifolin glycoside (TAX), in an AD model, the NC/Nga mouse. MethodsWe evaluated the efficacy of topical TAX for AD by measuring clinical skin severity score, cytokine expression and serum IgE level, and by using biomedical measures (vapometry and corneometry). Topical TAX was applied to AD-induced NC/Nga mice for 3weeks. The anti-inflammatory effects of this compound were demonstrated noninvasively using biomedical tools and immunological assays. ResultsOur method of AD assessment using biomedical tools is more objective and accurate than visual inspection. The results obtained using the biomedical tools were identical to those obtained using immunological assays. ConclusionsIn vivo biomedical tools are useful for diagnosing and monitoring treatment effects in AD. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | TOPICAL APPLICATION | - |
dc.subject | ANTIINFLAMMATORY ACTIVITY | - |
dc.subject | ANIMAL-MODELS | - |
dc.subject | MURINE MODEL | - |
dc.subject | MOUSE MODEL | - |
dc.subject | IFN-GAMMA | - |
dc.subject | INHIBITION | - |
dc.subject | EXPRESSION | - |
dc.subject | FLAVONOIDS | - |
dc.subject | CELLS | - |
dc.title | In vivo assessment of the effect of taxifolin glycoside on atopic dermatitis-like skin lesions using biomedical tools in NC/Nga mice | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, J. Y. | - |
dc.contributor.affiliatedAuthor | Oh, C. H. | - |
dc.identifier.doi | 10.1111/ced.12522 | - |
dc.identifier.scopusid | 2-s2.0-84931957771 | - |
dc.identifier.wosid | 000356628600016 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL DERMATOLOGY, v.40, no.5, pp.547 - 555 | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL DERMATOLOGY | - |
dc.citation.title | CLINICAL AND EXPERIMENTAL DERMATOLOGY | - |
dc.citation.volume | 40 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 547 | - |
dc.citation.endPage | 555 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | TOPICAL APPLICATION | - |
dc.subject.keywordPlus | ANTIINFLAMMATORY ACTIVITY | - |
dc.subject.keywordPlus | ANIMAL-MODELS | - |
dc.subject.keywordPlus | MURINE MODEL | - |
dc.subject.keywordPlus | MOUSE MODEL | - |
dc.subject.keywordPlus | IFN-GAMMA | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | FLAVONOIDS | - |
dc.subject.keywordPlus | CELLS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.